SpaceX IPO Filing Expected This Week as Valuation Could Surpass $75 Billion 
Rio Tinto's Resolution Copper Mine: U.S. Smelting Challenges and Global Operations Update 
UK Consumer Confidence Weakens Amid Middle East Conflict and Rising Living Costs 
Air Canada Express Crash at LaGuardia: Controller Distracted by Prior Emergency 
Merck's $6 Billion Bid for Terns Pharma Signals Bold Oncology Push 
Gold is meant to be a ‘safe haven’ in uncertain times. Why is it crashing amid a war? 
Nanya Technology Shares Surge 10% After $2.5 Billion Private Placement from Sandisk and Cisco 
Explosion and Fire Erupt at Valero Oil Refinery in Port Arthur, Texas 
Sonova Shares Slip as Hearing Aid Giant Lowers Growth Outlook and Plans Sennheiser Exit 
Nintendo Switch 2 Production Cut as Holiday Sales Miss Targets 
Finnair Orders 18 Embraer E195-E2 Jets in Landmark Fleet Overhaul 
9 Tips for Avoiding Tax Season Cyber Scams 
Currency Markets Show Caution Amid U.S.-Iran Negotiations 
Delivery Hero Sells Taiwan Foodpanda to Grab for $600 Million in Debt-Reduction Push 
Oil Prices Plunge Over 6% as Middle East Ceasefire Hopes Ease Supply Fears 
SLMG Beverages Eyes Price Hikes Amid Rising Packaging Costs and India's Booming Soft Drink Market 
Celltrion revealed on Thursday, Sept. 23, that it would be supplying its rapid COVID-19 test kit called DiaTrust to the US government. This happened after the nation’s Department of Defense awarded the contract to them.
The South Korean biopharma stated that starting October 1st, its American division, Celltrion USA, will begin delivering the DiaTrust rapid test kits to 25,000 locations. The sites include nursing homes, coronavirus testing centers, and military facilities.
According to The Korea Herald, based on the agreement signed by Celltrion and the US Defense Logistics Agency, the United States could purchase additional kits if necessary. For the initial supply, the amount of the contract is said to be $626.61 million or 738.2 billion in Korean won.
Details for the initial order, like how many would be delivered was not disclosed. However, the publication stated that Bloomberg mentioned that the deal was for a total of 19 million DiaTrust test kits. With its contract with the DOD, Celltrion became the US’ largest supplier of rapid COVID-19 test kits.
“The fact that we were awarded a procurement contract by the DLA after having passed its strict screen process is a recognition of Celltrion’s technology and supply capability,” Celltrion USA chief executive officer, Bonjoong Kim, said in a press release. “With the COVID-19 pandemic still not showing signs of waning, we plan to focus on executing this contract as diligently as possible and further solidify the external credibility of Celltrion’s diagnostic test kits portfolio.”
It was added that the DiaTrust kits that will be delivered through this deal are point-of-care tests (POCT). This means that the COVID-19 rapid test will only be used in the presence of medical professionals. Apparently, this is for safety and to ensure that the process is done properly for more accurate results.
As per Pulse News, DiaTrust was jointly developed by Celltrion and Humasis, a Korean R&D company. The test kit was authorized by the US Food and Drug Administration (FDA) for emergency use last April.
Finally, Celltrion’s DiaTrust rapid COVID-19 kit is an antigen test that is used in medical settings. It can reveal the results on the spot since it only takes as little as 15 minutes to complete.
